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Background
Following a clinical evaluation of deferasirox (Exjade®) it was concluded that, in addition to
baseline body iron burden, ongoing transfusional iron intake should be considered when select-
ing doses. The 1-year EPIC study, the largest ever investigation conducted for an iron chelator,
is the first to evaluate whether fixed starting doses of deferasirox, based on transfusional iron
intake, with dose titration guided by serum ferritin trends and safety markers, provides clini-
cally acceptable chelation in patients (aged ≥2 years) with transfusional hemosiderosis from
various types of anemia.
Design and Methods
The recommended initial dose was 20 mg/kg/day for patients receiving 2-4 packed red blood
cell units/month and 10 or 30 mg/kg/day was recommended for patients receiving less or more
frequent transfusions, respectively. Dose adjustments were based on 3-month serum ferritin
trends and continuous assessment of safety markers. The primary efficacy end-point was
change in serum ferritin after 52 weeks compared with baseline.
Results
The 1744 patients enrolled had the following conditions; thalassemia (n=1115), myelodysplas-
tic syndromes (n=341), aplastic anemia (n=116), sickle cell disease (n=80), rare anemias (n=43)
and other transfused anemias (n=49). Overall, there was a significant reduction in serum fer-
ritin from baseline (-264 ng/mL; P<0.0001), reflecting dosage adjustments and ongoing iron
intake. The most common (>5%) adverse events were gastrointestinal disturbances (28%) and
skin rash (10%).
Conclusions
Analysis of this large, prospectively collected data set confirms the response to chelation ther-
apy across various anemias, supporting initial deferasirox doses based on transfusional iron
intake, with subsequent dose titration guided by trends in serum ferritin and safety markers
(clinicaltrials.gov identifier: NCT00171821).
Key words: transfusion medicine, iron chelation therapy, transfusion-dependent anemias.
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Introduction
Chronic iron overload is a serious complication of the
repeated blood transfusions that are necessary for the
treatment of patients with blood disorders such as tha-
lassemia, sickle cell disease (SCD), myelodysplastic syn-
dromes (MDS) and various other rare anemias, including
aplastic anemia (AA). Without chelation therapy, excess
iron accumulates in the body, leading to organ failure,
particularly of the liver, heart and endocrine glands.1,2
Following extensive clinical research in the management
of iron overload, patients with thalassemia major receiv-
ing effective chelation therapy were found to have signif-
icant improvements in survival.3 Preliminary data also
suggest a potential  survival benefit in lower-risk MDS
patients receiving chelation therapy.4,5
In prior studies evaluating the efficacy and safety of
deferasirox, dosing was based on baseline liver iron con-
centration (LIC) as assessed by either liver biopsy, super-
conducting quantum interference device (SQUID) or
magnetic resonance imaging (MRI).6-10 Biopsies are
uncomfortable for the patient, particularly the elderly,
and can lead to complications such as bleeding and infec-
tion, especially in MDS or AA patients with hemostatic
impairment.11,12 The consistency of results obtained from
studies measuring the accuracy of LIC by SQUID is gen-
erally poor, with the underestimation of SQUID-deter-
mined LIC compared with biopsy-determined LIC being
a critical factor.13 Measurement of LIC by MRI is not used
routinely as it requires special software and expertise and
is often unavailable or relatively expensive in many
regions worldwide. Hence, serum ferritin concentration
remains a convenient,  less expensive and widely used
way of assessing body iron and, when followed serially,
is a suitable alternative marker of trends in body iron bur-
den as significant correlations between changes in LIC
and serum ferritin have been identified in various types of
anemia.6,9,14 Post-hoc analyses of 1-year phase III
deferasirox data suggested that, in addition to baseline
LIC, ongoing transfusional iron intake is an important fac-
tor when selecting initial doses and making dose adjust-
ments during the course of iron chelation therapy.15 This
is particularly important as the average transfusional iron
intake in patients with thalassemia, MDS and SCD varies
considerably; thus, the duration and rate of iron loading
should also be considered.9,10,15
The multicenter Evaluation of Patients’ Iron Che lation
with Exjade (EPIC) study is the first prospective study
to evaluate whether the practical approach of fixed
starting doses of deferasirox, based on ongoing iron
intake from blood transfusions, followed by subsequent
dose titration every 3 months according to serum fer-
ritin trends and safety markers, could provide effective
chelation as assessed by a decline in serum ferritin. EPIC
is the largest prospective study conducted on an iron
chelator to date, providing data on diverse and large
cohorts of iron-overloaded patients with thalassemia
and other rare transfusion-dependent anemias. 
Design and Methods
Inclusion and exclusion criteria
Male or female patients (aged ≥2 years) with transfusional iron
overload (independently of the underlying condition) as shown by
a serum ferritin level of 1000 ng/mL  or more, or less than 1000
ng/mL but with a history of multiple transfusions (>20 transfu-
sions or 100 mL/kg of red blood cells) and R2 MRI-confirmed LIC
of or exceeding 2 mg of Fe/g dry weight (dw), were eligible for
inclusion. Pediatric patients had to be of sufficient weight to
receive the smallest strength tablet at their allocated dose (i.e. 125
mg). Patients with levels of alanine aminotransferase (ALT) above
300 U/L, uncontrolled systemic hypertension, serum creatinine
above the upper limit of normal (ULN), a history of nephrotic syn-
drome, a previous history of clinically relevant ocular toxicity relat-
ed to iron chelation, systemic diseases (cardiovascular, renal,
hepatic) or any surgical or medical condition that could affect
absorption of defera sirox were excluded from the study. Patients
were also excluded if they had been treated with systemic or top-
ical investigational drugs within the preceding 4 weeks or 7 days,
respectively, or a had a history of drug or alcohol abuse within the
past 12 months or a history of non-compliance to medical regi-
mens. Patients (or pa rents/guardians) provided written, informed
consent before entering the study. The study was conducted in
accordance with Good Clinical Practice guidelines and the
Declaration of Helsinki. A Study Monitoring Com mittee super-
vised the trial conduct and made decisions regarding exceptional
dose adjustments for individual patients. This study was conduct-
ed between April 2005 and June 2008.
Study design
EPIC was a prospective, 1-year, multicenter, open-label phase
IIIb trial conducted by 136 investigators across 23 countries.
Patients previously receiving deferiprone discontinued treatment
at least 28 days before entering the study (washout period) but
could switch to deferoxamine during this time. Patients were per-
mitted deferoxamine until 1 day immediately prior to study entry. 
The starting dose of deferasirox was individualized based on
the frequency of blood transfusions. The recommended initial
dose was 20 mg/kg/day for patients receiving  approximately 2-4
units of packed red blood cells/month (7-14 mL/kg/month for a
body weight of ~60 kg, equivalent to 0.3-0.5 mg/kg/day). An ini-
tial dose of 30 mg/kg/day could be considered for patients receiv-
ing blood transfusions more frequently and a reduced dose of 10
mg/kg/day could be considered for patients receiving blood trans-
fusions less frequently. Dose increases were recommended in
patients with baseline serum ferritin values of more than 500
ng/mL and demonstrating an increasing trend or with baseline
serum ferritin values of more than 1000 ng/mL with no down-
ward trend after 3 months. The increasing or decreasing trends
were judged by the individual investigators. Specific dose adjust-
ment recommendations were provided based on continuous
assessment of safety markers including changes in serum creati-
nine, urinary protein:urinary creatinine ratio, liver function tests,
development of skin rash, auditory and ocular disturbances,
cytopenias and hypersensitivity reactions. These dose adjust-
ments were recommended in steps of 5-10 mg/kg/day (in the
range of 0-40 mg/kg/day). The dose could be escalated above 40
mg/kg/day in exceptional cases and this had to be approved on an
individual basis by the Study Monitoring Committee. If serum fer-
ritin levels were 500 ng/mL or below on two consecutive study
visits, deferasirox treatment was suspended until levels returned
to above 500 ng/mL. 
Assessments
The primary efficacy end-point was the difference in serum fer-
ritin concentration after 52 weeks of treatment compared with
baseline. Serum ferritin was assessed at the beginning of the run-
in period (days -35 to -1) and then every 4 weeks. Baseline serum
ferritin was taken as the average of the available measurements
within 28 days prior to the start of treatment. Secondary efficacy
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end-points included the absolute change in serum ferritin levels
from baseline to the end of the study in each disease cohort and
evaluation of the relationship between dose adjustment regimens
and transfusional iron overload. Safety was evaluated through the
continuous monitoring and recording of adverse events and seri-
ous adverse events, as well as through routine laboratory assess-
ments and physical examination. Records of study medication
used, dosages administered, all dispensed and returned study
medication and intervals between visits were kept during the
study to determine treatment compliance.
Statistical methods 
Power calculations indicated that a total sample size of 1541
patients was required to achieve a study power of 80% to demon-
strate an overall one-sided α significance level of 0.025 that the
mean value of serum ferritin decreased at the end of study com-
pared to baseline. This was based on the assumption that the
expected difference would be greater than 100 ng/mL and the
standard deviation of the differences was 1400 ng/mL. Efficacy
was assessed for the full analysis set, including all patients who
had been successfully screened and started the study. If there was
no serum ferritin value available at 52 weeks, the last available
observation was used as the end of study assessment to calculate
change from baseline (last-observation-carried-forward [LOCF]
analysis) thus providing a robust, yet conservative end-point to
cope with the intention-to-treat principle. Reported P values for
the investigation are based on two-sided paired t-tests or the
Kruskall Wallis test. All patients who received at least one dose of
study medication were included in the safety analysis. 
Results
Patients’ characteristics
A total of 1744 patients were enrolled (Table 1). The
underlying diseases necessitating chelation therapy were
thalassemia (63.9%), MDS (19.6%), AA (6.7%), SCD
(4.6%), other rare anemias (predominantly pure red cell
aplasia and hemolytic anemias; 2.5%) and various condi-
tions requiring transfusion, including malignant diseases
[primarily acute myeloid leukemia (n=16) and congenital
anemia; 2.8%]. Overall, 79.6% of patients (n=1389) com-
pleted 1 year of treatment. Treatment discontinuation
rates (Figure 1) were lowest among thalassemia patients
(9.4%), and highest among MDS patients (48.7%).
Baseline median serum ferritin levels in all subgroups
were greater than 2500 ng/mL, which is a threshold
known to be associated with significant negative out-
comes (Table 1). The median length of time that patients
had been transfusion-dependent was 9.0 years; however,
this was longer in thalassemia patients (median 15.0
years). The duration of transfusion dependency was com-
paratively brief in MDS patients at a median of only 3.0
years. Although SCD patients had been transfusion
dependent for a median of 10.0 years, the amount of
blood received during the year prior to study entry was
the lowest at 84±57 mL/kg. Most patients had received
prior chelation therapy (Table 1); however, a large propor-
tion of patients with AA, MDS and other anemias were
chelation-naïve (68%, 48% and 61%, respectively).
Exposure to treatment
Overall, 27 patients (1.5%) started on 10 mg/kg/day, 1527
(87.6%) on 20 mg/kg/day and 189 (10.8%) on 30
mg/kg/day. The deferasirox dose was adjusted from the
planned dose during the study in 1303/1744 patients
(74.7%). Doses were increased in 672 patients (39%) at a
median of 24 weeks after treatment initiation (range, 2-53).
The first dose increase was performed at or less than 3
months of starting treatment in 82 patients (12.2%),
between 3 and 6 months after starting treatment in 332
patients (49.4%), between 6 and 9 months in 158 patients
(23.5%) and more than 9 months after starting treatment in
100 patients (14.9%). The most common dose increase was
from 20 to 25 mg/kg/day (291 patients) (Online
Supplementary Figure S1). Doses were reduced in 198
patients (11.4%) and temporarily interrupted in 425
patients (24.4%) due to laboratory abnormalities or adverse
events. Fifteen patients (0.9%) discontinued treatment as
they no longer required the study drug since their serum
ferritin levels were 500 ng/mL or lower on two consecutive
visits. Of the 1389 patients completing the study, 131
patients (9.4%) were receiving less than 20 mg/kg/day, 550
(39.6%) were receiving from 20 mg to less than 30
mg/kg/day, and 708 (51.0%) were receiving 30 mg/kg/day
or more. Compliance was greater than 80% in 85.3% of the
patients.
The mean actual dose received over the course of the
study was 22.2±5.9 mg/kg/day for a median of 52.1
(range, 50.9-64.4) weeks. The mean dose and median
change in serum ferritin during the 1-year treatment peri-
od by mean actual dose category are shown in Figure 2.
The majority of patients (66%) in the thalassemia group
received a higher daily deferasirox dose of from 20 mg to
less than 30 mg/kg/day, whereas many patients (~50-
60%) in all other disease cohorts received less than 20
mg/kg/day (Online Supplementary Table S1). 
Transfusional iron intake
Over the course of the 1-year study, patients received a
mean of 116.3±72.4 mL red blood cells/kg, equivalent to
0.41 mg/kg/day of iron. The mean transfusional iron
intake was highest in the thalassemia, MDS and rare ane-
mia groups (0.43, 0.42 and 0.49 mg/kg/day, respectively)
and approximately 0.25 mg/kg/day in the SCD and AA
groups (Table 2). Transfusional iron intake was significant-
ly different across deferasirox dose cohorts in the total
population of patients (P<0.0001, Kruskall Wallis test).
Effect of deferasirox on serum ferritin
LOCF data indicated that median serum ferritin levels
decreased significantly from baseline by a median of 264
ng/mL (P<0.0001; Table 3) after 1 year of defe ra sirox treat-
ment with a mean actual dose of 22.2 mg/kg/day and
mean transfusional iron intake of 0.41 mg/kg/day. The
extent of reduction in serum ferritin reflected the dosage
adjustments applied at a median of 6 months after treat-
ment initiation and iron intake over the course of the
study. In patients with no initial drop in serum ferritin [i.e.
requiring dose increases to above 20 mg/kg/day (n=9729
with a resulting mean actual dose of from 20 mg to less
than 30 mg/kg/day over the course of the study], there
was a significant reduction in serum ferritin of 198 ng/mL
(P=0.0130) while receiving a mean transfusional iron
intake of 0.44 mg/kg/day. Other patients (n=586) having
drops in serum ferritin within 3 months received a mean
actual dose of less than 20 mg/kg/day; at 12 months,
median serum ferritin was significantly reduced in these
patients (-279 ng/mL; P<0.0001) with a mean transfusion-
al iron intake of 0.36 mg/kg/day. Patients receiving doses
haematologica | 2010; 95(4) 559
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of 30 mg/kg/day or more over the course of the study
(n=149), had a more substantial reduction in serum ferritin
of 882 ng/mL (P<0.0001) with a mean transfusional iron
intake of 0.37 mg/kg/day. A similar pattern of serum fer-
ritin changes, reflecting dose adjustments and mean iron
intake, was seen across all underlying anemias. A similar
response was noted in the full analysis set of patients
including all patients who had been successfully screened
and started the study (Figure 2A–D). 
Safety
Adverse events, irrespective of their relation to the
study drug, were reported in 1477 (84.7%) patients, with
the most common being diarrhea (22.5%), rash (13.3%),
abdominal pain (12.2%) and nausea (12.7%). The most
common adverse events leading to discontinuation of the
study drug were rash (n=22; 1.3%) and diarrhea (n=8;
0.5%). Adverse events considered to be drug-related by
the investigator were reported in 877 (50.3%) patients;
most of these events were of mild-to-moderate severity
and resolved without treatment needing to be discontin-
ued. The most common drug-related adverse events
were diarrhea (14.4%), skin rash (10.0%), and nausea
(7.7%) (Table 4). Drug-related adverse events were par-
ticularly common in patients with rare anemias (69.8%),
other anemias (67.3%) and MDS (66.3%), with diarrhea
being the most common adverse events in these patients.
Deafness, hearing impairment or hypoacusis were
reported as adverse events in 10 (0.6%) patients, irre-
spective of a relationship with the drug; two (0.1%)
cases were considered by the investigators to be drug-
related. Cataracts were reported as adverse events in two
patients (0.1%); in both cases the adverse event was con-
sidered unrelated to the study drug. There were 90
reports of arthralgia, 10 of which (0.6%) were considered
by the investigators to be drug-related. Serious adverse
events, irrespective of causality, were reported in 336
patients (19.3%); the most common of these serious
adverse events were pyrexia (n=51; 2.9%), abdominal
pain (n=31; 1.8%), pneumonia (n=23; 1.3%) and sepsis
(n=20; 1.1%). Drug-related serious adverse events (as
assessed by the investigator) were reported in 30 patients
(Online Supplementary Table S2), the most common being
rash (n=7). 
There were 42 (2.4%) deaths after the start of study
treatment, none of which was considered, by the investi-
gators, to be related to the study drug. Twenty-six deaths
occurred in MDS patients, with the causes including hem-
orrhage (n=4) and septic shock (n=3) (Online Supplementary
Table S3); five occurred in AA patients and were caused by
sepsis (n=3), pneumonia (n=1) and rupture of a hepatic
adenoma (n=1); four occurred in thalassemia patients and
were due to heart failure (n=3) and septicemia following
surgery (n=1), and seven occurred in patients with other
rare anemias, in whom the causes were acute respiratory
failure, bladder tumor, sepsis, heart failure, hemolytic ane-
mia, progressive (malignant) disease and septic shock (all
n=1). 
Overall, 175 (10.0%) patients had two consecutive
serum creatinine increases of more than 33% above base-
M.D. Cappellini et al.
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Figure 1. Disposition of patients. *All patients who were successfully screened and started treatment were included in the intent-to-treat
analysis and last-observation-carried-forward (LOCF) analysis was used as the end of study efficacy assessment.
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line and above the ULN; there was no progressive increase
in mean serum creatinine (Table 4). The risk of having two
consecutive serum creatinine increases of more than 33%
above baseline and above the ULN was higher if the base-
line serum creatinine concentration was high. The
deferasirox dose was decreased within 30 days of the cre-
atinine increase episode in 58/175 patients (33.1%) and
temporarily interrupted in 19/175 patients (10.9%). Three
patients discontinued treatment with the study drug
because of increases in serum creatinine. Overall, 11 cases
of drug-related proteinuria (0.6%) were reported during
the study (thalassemia n=6; MDS n=3; AA n=1; rare ane-
mias n=1). There was one case of acute renal failure
assessed as a drug-related serious adverse event (Online
Supplementary Table S2). Thirteen (0.7%) patients experi-
enced two consecutive increases in ALT over ten times the
ULN; however, levels were already elevated at baseline in
11 of these patients (Table 4). Dose adjustments based on
elevated ALT at baseline and after deferasirox therapy
were not performed in eight of these 11 patients; ALT lev-
els resolved in six of these patients (ALT levels were less
than the ULN by the last observation). Deferasirox dose
was decreased and/or temporarily interrupted in five
patients; the abnormality in ALT level resolved in two of
these patients, two had initial signs of improvement, but
ALT levels increased when deferasirox was resumed or
increased and one patient had no improvement in ALT
levels.
Discussion 
The results of this large-scale study confirm the efficacy
of deferasirox in reducing serum ferritin levels in patients
with a wide range of transfusion-dependent anemias.6,9,10
Serum ferritin was significantly decreased in the overall
population and in all disease subgroups, except for SCD.
The observed reduction in serum ferritin reflected the
One-year results from the deferasirox EPIC study
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Table 1. Demographic and baseline characteristics of the patients. 
Thalassemia MDS AA SCD Rare anemias Others All patients
(n=1115) (n=341) (n=116) (n=80) (n=43) (n=49) (n=1744)
Mean age (range), years 18.2 (2-72) 67.9 (11-89) 33.3 (2-79) 23.9 (4-60) 39.5 (2-82) 50.3 (4-83) 30.6 (2-89)
Male:female, n 538:577 204:137 67:49 39:41 20:23 33:16 901:843
Race (Caucasian:oriental:other), n 468:594:53 309:30:2 32:80:4 18:15:47 30:11:2 38:10:1 895:740:109
History of hepatitis B and/or C, n (%) 275 (24.7) 11 (3.2) 8 (6.9) 19 (23.8) 4 (9.3) 2 (4.1) 319 (18.3)
Splenectomy, n (%) 395 (35.4) 13 (3.8) – 22 (27.5) 12 (27.9) 6 (12.2) 448 (25.7)
Previous chelation therapy, n (%)
DFO monotherapy 763 (68.4) 137 (40.2) 31 (26.7) 50 (62.5) 24 (55.8) 17 (34.7) 1022 (58.6)
Deferiprone monotherapy 12 (1.1) 14 (4.1) – 1 (1.3) 1 (2.3) – 28 (1.6)
DFO + deferiprone 245 (22.0) 24 (7.0) 6 (5.2) 10 (12.5) 5 (11.6) 2 (4.1) 292 (16.7)
Deferasirox 4 (0.4) 1 (0.3) – – – – 5 (0.3)
None 95 (8.5) 165 (48.4) 79 (68.1) 19 (23.8) 13 (30.2) 30 (61.2) 401 (23.0)
Median duration of previous 7.8 (2.9,16.1) 1.4 (0.5, 2.6) 2.2 (0.7, 4.4) 6.3 (3.2, 12.4) 1.1 (0.4, 7.0) 1.1 (0.5, 4.5) 5.7 (1.8, 13.5)
ICT (25th, 75th percentiles), years
Median duration of transfusion 15.0 (8.0, 23.0) 3.0 (1.0, 4.0) 5.0 (2.0, 8.0) 10.0 (6.5, 17.0) 5.5 (2.0, 14.0) 2.0 (1.0, 6.0) 9.0 (3.0, 19.0)
therapy (25th, 75th percentiles), years
Mean±SD transfusion sessions 16.6±8.6 24.3±17.7 12.5±13.0 10.7±8.2 21.0±18.7 23.6±20.7 17.8±12.5
in year prior to study entry* 
Mean±SD total volume of red 183±133 116±123 116±179 84±57 153±142 148±124 159±136
blood cells transfused in year prior 
to study entry*, mL/kg 
Median baseline serum ferritin, 3188 2730 3254 3163 3161 3010 3135
ng/mL (range) (462-22320) (951-9465) (908-25346) (579-12835) (568-13078) (1173-17053) (462-25346)
*Information on the number of transfusions is only available for the year prior to study entry. DFO, deferoxamine; ICT, iron chelation therapy.
Table 2. Mean transfusional iron intake (mg/kg/day) by mean actual dose. 
Mean average actual Thalassemia MDS AA SCD Rare anemias Others All patients
dose (mg/kg/day)
<20 0.38±0.28 0.38±0.4 0.21±0.18 0.28±0.24 0.43±0.55 0.42±0.34 0.36±0.34
Mean iron intake±SD, mg/kg/day (n) (n=238) (n=196) (n=75) (n=41) (n=26) (n=23) (n=609)
≥20-<30 0.45±0.22 0.47±0.45 0.31±0.2 0.24±0.13 0.56±0.86 0.41±0.52 0.44±0.29
Mean iron intake±SD, mg/kg/day (n) (n=736) (n=135) (n=41) (n=39) (n=17) (n=12) (n=984)
≥30 0.35±0.15 0.64±0.34 − − − − 0.37±0.17
Mean iron intake±SD, mg/kg/day (n) (n=141) (n=9) (n=150)
All patients 0.43±0.23 0.42±0.43 0.25±0.19 0.26±0.19 0.49±0.7 0.42±0.4 0.41±0.3
Mean iron intake±SD, mg/kg/day (n) (n=1115) (n=340) (n=116) (n=80) (n=43) (n=35) (n=1743)
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dosage adjustments (which occurred relatively late at a
median of 24 weeks) and mean iron intake over the course
of the study. Patients who received an average actual
deferasirox dose of less than 20 mg/kg/day during the
study had a lower transfusional iron intake than those
who received an average actual dose of from 20 to less
than 30 mg/kg/day. Gradual dose up-titration was
required in many patients to achieve a negative iron bal-
ance and a reduction in serum ferritin below baseline by
12 months. Patients who received an average actual dose
of 30 mg/kg/day or more had the greatest reduction in
serum ferritin levels, which reflects more appropriate dos-
ing from the start of the study in patients with higher iron
burden and transfusional iron intake. These data therefore
support the clinical approach of initial dose selection of
deferasirox according to transfusion requirements and
highlights the need for prompt dose titration every 3
months based on trends in serum ferritin levels and mark-
ers of safety. Patients with thalassemia formed the largest
cohort (63.9%) included in this study and had a significant
(P<0.0001) reduction in serum ferritin levels, primarily
driven by the significant reduction in the levels among
patients who received an average actual dose of 30
mg/kg/day or more. Modest reductions in serum ferritin in
the two lower dose groups may have resulted from
delayed dose adjustments (median of 24 weeks) and the
fact that dose increases were recommended, and not man-
dated, in the protocol at every 3 months. These findings
are consistent with previous studies of deferasirox in tha-
lassemia patients showing that higher doses are needed
because of high iron burden and transfusional require-
ments in this population of patients.16,17 The ESCALATOR
study in heavily transfused and iron-overloaded patients
with β-thalassemia showed that significant reductions in
serum ferritin to below 2500 ng/mL were achieved follow-
ing longer-term treatment with optimal doses of 25-30
mg/kg/day.17
Our study also enabled an evaluation of chelation ther-
apy in reducing serum ferritin in large groups of patients
with MDS, AA and other rare anemias, in whom studies
have been limited to date.18-20 Data from the 341 MDS
patients enrolled demonstrated that a mean deferasirox
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Table 3. Median (range) change from baseline in serum ferritin (ng/mL) by mean actual dose.
Mean actual Thalassemia MDS AA SCD Rare anemias Others All patients
dose (mg/kg/day)
<20 
Baseline 2356 2535 3263 2615 2572 2976 2608
(462-20788) (951-9193) (908-18635) (579-7274) (568-13078) (1173-17053) (462-20788)
Change from baseline* -45 274 -970 -235 -846 -434 -279
(-6010 to 9501) (-6040 to 6124) (-11753 to 7883) (-2315 to 2707) (-4466 to 3939) (-8846 to 4285) (-11753 to 9501)
n=231 n=183 n=75 n=39 n=25 n=33 n=586
P versus baseline* 0.2884 0.0012 <0.0001 0.4356 0.0174 0.1073 <0.0001
≥20-<30 
Baseline 3160 2995 3238 3596 4248 3154 3165
(480-22320) (1086-9465) (1129-25346) (1547-12835) (1321-10832) (1873-8067) (480-25346) 
Change from baseline* -93 -219 -884 -72 -771 -881 -198
(-7837 to 7933) (-7125 to 14145) (-15704 to 13894) (-3728 to 2846) (-4522 to 7064) (-3509 to 2166) (-15704 to 14145)
n=732 n=130 n=40 n=39 n=17 n=14 n=972
P versus baseline* 0.2062 0.1730 0.2777 0.4161 0.4452 0.0543 0.0130
≥30 
Baseline 5093 4279 − − − − 5048
(1326-16944) (1922-8980) (1326-16944)
Change from baseline* -926 -638 − − − − -882
(-10282 to 7680) (-1623 to 2580) (-10282 to 7680)
n=141 n=8 n=149
P versus baseline* <0.0001 0.6266 − − − − <0.0001
All patients
Baseline 3188 2730 3254 3163 3161 3010 3135
(462-22320) (951-9465) (908-25346) (579-12835) (568-13078) (1173-17053) (462-25346)
Change from baseline* -163 -253 -964 -225 -832 -620 -264
(-10282 to 9501) (-7125 to 14145) (-15704 to 13894) (-3728 to 2846) (-4522 to 7064) (-8846 to 4285) (-15704 to 14145)
n=1104 n=321 n=115 n=78 n=42 n=47 n=1707
P versus baseline* <0.0001 0.0019 0.0003 0.2588 0.0275 0.0235 <0.0001
*Based on last-observation-carried-forward (LOCF) analysis. Presented serum ferritin values are median (range). 
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dose of 19.2 mg/kg/day was associated with a significant
reduction in serum ferritin (P<0.05). Data from the large
groups with AA and rare anemias were also encouraging,
indicating a reduction in serum ferritin from baseline with
a mean deferasirox dose of 17.6 and 18.6 mg/kg/day,
respectively. Many patients with MDS, AA and rare ane-
mias were chelation-naïve despite being heavily iron over-
loaded, indicating a need for greater awareness of the
potential impact of iron overload in these groups of
patients.
SCD patients had received transfusion therapy for more
than 50% of their lifetime, with elevated serum ferritin
levels. The reduction in serum ferritin after 1 year of
deferasirox was not statistically significant, possibly
because of the small number of patients. In addition,
serum ferritin levels can be affected by inflammatory
processes,21 which SCD patients are prone to as a conse-
quence of sickling crises, and these may cause intra-
patient variability in serum ferritin results.10,22-24
Measurement of LIC by biopsy or MRI may, therefore, be
a more reliable measure for monitoring tissue iron burden
in these patients, as recommended in the UK guidelines.23
While assessment of LIC by biopsy provides a direct
measurement of body iron, this invasive procedure does
have limitations. MRI, although non-invasive, is not wide-
ly available worldwide. Serial measurements of serum fer-
ritin provide a simple, generally reliable, indirect measure
of total body iron which is accessible worldwide and inex-
pensive and has also been shown in several studies to cor-
relate with LIC measurements in patients with tha-
lassemia major.6,14 The data reported in the present study
indicate that serial measurements are useful for monitor-
ing chelation therapy with deferasirox to alter doses
according to ongoing iron loading through transfusion.
The deferasirox prescribing information recommends that
serum ferritin be monitored monthly to assess the
patient’s response to therapy and that the dose of
deferasirox be adjusted if necessary every 3 to 6 months
based on these trends.25 Data from this trial are based on
the pre-planned analysis of absolute change in serum fer-
ritin from baseline. However, the clinical relevance of such
changes may vary depending on a patient’s baseline serum
ferritin levels. It would be valuable to evaluate serum fer-
ritin trends relative to grouped baseline serum ferritin val-
ues. These analyses are planned to be run in the near
future.
The safety of deferasirox has been shown in patients
with a variety of underlying anemias in a number of stud-
ies.6,7,9,10 In the present study, deferasirox was generally
well tolerated with a clinically manageable side-effect pro-
file. The adverse events reported in this 1-year study were
predominantly gastrointestinal disturbances and skin rash-
es, which are consistent with previous observations from
deferasirox trials.6-10 A recent analysis of data from four
deferasirox studies showed that the safety profile of
deferasirox in patients who received more than 30
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Figure 2. Mean actual deferasirox dose±SD (mg/kg/day) and median change in serum ferritin±25th and 75th percentiles (ng/mL) during the
study by average actual dose categories in the full analysis set of patients. (A) All patients. (B) Patients on a dose <20 mg/kg/day. (C)
Patients on a dose ≥20–<30 mg/kg/day. (D) Patients on a dose ≥30 mg/kg/day.
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mg/kg/day is consistent with that of patients who
received doses below 30 mg/kg/day.26 Importantly this
analysis also showed that there were no adverse events
observed following escalation to over 30 mg/kg/day that
were not observed at lower doses.26 This is the first study
to specifically assess the safety profile of deferasirox
according to the underlying anemia in larger numbers of
patients than previously reported9 and the findings suggest
that there may be differences in side-effect profiles
between patients with different types of anemia. There
was a higher incidence of drug-related adverse events and
higher treatment discontinuation rates in patients in the
MDS cohort than in patients with other underlying ane-
mias, although this adverse event profile was consistent
with data from previous studies in MDS patients.9,27 This
may be related to the risk of disease progression, pre-
existing co-morbidities, concomitant medication use and
the advanced age of patients with MDS. Drug-related
adverse events were also more frequently reported in
patients with rare anemias perhaps because the majority
of patients were chelation-naïve and more prone to
reporting mild symptoms such as diarrhea, nausea and
abdominal pain. Evaluating adverse event frequency by
underlying anemia and dose would, therefore, be of inter-
est and warrants further analysis. 
Increases in mean serum creatinine or liver transaminas-
es were managed effectively in this large study and there
were no progressive increases. Reported increases in these
laboratory parameters were similar to those observed in
previous studies irrespective of different dose interven-
tions between trials, confirming the renal and hepatic safe-
ty profile of deferasirox across various types of anemias
and at a range of doses.6,9 
In conclusion, this large study is the first to support the
clinical approach of using a specified starting dose of
deferasirox based on transfusion requirements, and high-
lighting the need for timely individual dose titration every
3 months according to serum ferritin trends and markers
of safety, underscoring the importance of early and
prompt dose increases to achieve a therapeutic goal of
reduction in serum ferritin. This study confirms that with
appropriate dosing, deferasirox is generally well tolerated
and effective in reducing serum ferritin levels in iron-over-
loaded, regularly transfused patients with a wide range of
underlying anemias, including thalassemia, MDS, AA and
other rare anemias. The results should provide clinicians
using deferasirox with a framework for evaluating chela-
tion requirements, using serum ferritin and safety mark-
ers, to make decisions on dose adjustments and tailoring
deferasirox treatment to achieve therapeutic goals of
reduction or maintenance of body iron levels.
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Table 4. Safety results by underlying disease.
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*Baseline creatinine levels were considered low, normal and high compared with the normal age– and gender–dependent range.
©F
err
ata
 S
tor
ti F
un
da
tio
n
and provided their comments on it. MDC, AE-B, C-KL, JS
and AK served as Study Monitoring Committee members
overseeing the conduct of the trial. DH and GD coordi-
nated the execution of the trial and contributed to the
analysis, interpretation, and reporting of the trial data. BR
served as the trial statistician.
MDC and K-HL report receiving lecture fees from
Novartis Pharmaceuticals. JP reports receiving consulting
fees, research grant funding and lecture fees from Novartis
Pharmaceuticals and consulting fees from Vifor
International and Mundipharma. AE-B reports receiving
research grant support, consulting fees and lecture fees
from Novartis Pharmaceuticals and research support and
honoraria from ApoPharma Inc. NG, SLT, AT and CR
report receiving research grant support and lecture fees
from Novartis Pharmaceuticals. LLC reports receiving
research grant support and lecture fees from Novartis
Pharmaceuticals and research grant support from
ApoPharma Inc. VV reports receiving research grant sup-
port and lecture fees from Novartis Pharmaceuticals and
research grant support from Government Pharmaceutical.
AK reports receiving research grant support, consulting
fees and lecture fees from Novartis Pharmaceuticals and
consulting fees and lecture fees from Apotex Research Inc.
C-KL reported receiving consulting and lecture fees from
Novartis Pharmaceuticals. DH, GD and BR are full-time
employees of Novartis Pharmaceuticals. No other poten-
tial conflicts of interests relevant to this article were
reported. 
Appendix: participating centers 
and investigators
L. Agaoglu, Istanbul University, Medical Faculty, Capa, Istanbul, Turkey; G.
Alimena, Az. Policlinico Umberto I, Roma, Italy; D. Alonso, Hospital Universitario
Virgen del Rocio, Sevilla, Spain; S. Ame, Hôpital Hautepierre, Strasbourg,
France; E. Angelucci, Ospedale Oncologico A. Businco, Cagliari, Italy; B.
Arrizabalaga, Hospital de Cruzes, Barakaldo, Spain; M. Athanasiou-Metaxa,
Aristotle University of Thessaloniki, Thessaloniki, Greece; B. Augustson, Sir
Charles Gairdner Hospital, Perth, Australia; Y. Aydinok, Ege University, Medical
Faculty, Bornova, Izmir, Turkey; A. Baba, Hospital University Sains Malaysia,
Kota Bahru, Malaysia; M. Baccarani, Az. Ospedaliera di Bologna, Malpighi,
Bologna, Italy; J. Beck, Klinikum der Universität Mainz, Mainz, Germany; P.
Beris, Hôpitaux Universitaires de Genève, Geneva, Switzerland; O. Beyne-
Rauzy, Hôpital Purpan, Toulouse, France; H. Birgens, Amtssygehuset l Herlev,
Herlev, Denmark; D. Bordessoule, CHU Limoges, Limoges, France; C. Borgna-
Pignatti, Az. Osp. Universitaria Sant'Anna, Ferrara, Italy; A. Bosly, Cliniques
Universitaires U.C.L., Godinne, Belgium; K. Bouabdallah, CHU Bordeaux,
Bordeaux, France; D. Bowden, Monash Medical Centre, Melbourne, Australia;
D. Bowen, Leeds General Infirmary, Leeds, UK; D. Bron, Institut Jules Bordet,
Brussels, Belgium; M. Capra, Ospedale Civico G. di Cristina M. Ascoli, Palermo,
Italy; G. Cartron, Clinique Victor Hugo, Le Mans, France; M. Cazzola,
Policlinico S. Matteo IRCCS, Pavia, Italy; C. Chalkias, General Hospital of
Larissa, Larissa, Greece; S. Chancharunee, Ramathibodi Hospital, Mahidol
University, Bangkok, Thailand; C. Chapman, Leicester Royal Infirmary, Leicester,
UK; P. Charoenkwan, Chiang Mai University, Chiang Mai, Thailand; E.
Chasapopoulou, University Hospital of Thessaloniki AHEPA, Thessaloniki,
Greece; S. Cheze, CHR Clemenceau, Caen, France; A. Chuansumrit,
Ramathibodi Hospital, Mahidol University, Bangkok, Thailand; P. Cianciulli,
Ospedale S. Eugenio, Roma, Italy; C. Dauriac, CHRU Rennes, Hôpital
Pontchaillou, Rennes, France; M. Delforge, UZ Gasthuisberg, Leuven, Belgium;
G. Dölken, Ernst-Moritz-Arndt-Universität Greifswald, Greifswald, Germany;
H. Dombret, Hôpital Saint Louis, Paris, France; J. Duyster, Klinikum rechts der
Isar der TU München, München, Germany; T. Economopoulos, Athens University
Medical School, Xaidari, Greece; G. Ehninger, Universitätsklinikum Dresden,
Dresden, Germany; L. Enggaard, Hillerod Sygehus, Hillerod, Denmark; P.
Fenaux, Hôpital Avicenne, Bobigny, France; G. Fillet, Centre Hospitalier
Universitaire Sart Tilman, Liège, Belgium; A. Filosa, Az. Osp. A. Cardarelli,
Napoli, Italy; G. Forni, Ospedale Galliera, Genova, Italy; R. Galanello,
Ospedale Regionale Microcitemie, Cagliari, Italy; A. Ganser, Kliniken der Med.
Hochschule Hannover, Hannover, Germany; G. Gastl, Uni-Klinik Innsbruck,
Innsbruck, Austria; A. Goldfarb, Hadassah Medical Centre, Jerusalem, Israel; A.
Grigg, Royal Melbourne Hospital, Melbourne, Australia; A. Guerci-Bresler, CHU
Nancy, Vandoeuvre Les Nancy, France; F. Gumruk, Hacettepe University,
Medical Faculty, Sihhiye, Ankara, Turkey; S. Y. Ha, Queen Mary Hospital,
Hong Kong, Hong Kong; D. Haase, Universitätsklinikum Göttingen, Göttingen,
Germany; B. Heinrich, Gemeinschaftspraxis Brudler/Heinrich, Ausburg,
Germany; M. Hertzberg, Westmead Hospital, Sydney, Australia; J. Ho, Royal
Prince Alfred Hospital, Sydney, Australia; H-C. Hsu, Taipei Veterans General
Hospital, Taipei, Taiwan; S. Huang, Guang Zhou Zhong Shan No.2 Hospital,
Guangzhou, China; M. Hunault-Berger, CHU d'Angers, Angers, France; B.
Inusa, Evelina Childrens Hospital, London, UK; D. Jaulmes, Hopital Saint
Antoine-Paris, Paris, France; J. Jensen, Arhus Sygehus, Arhus, Denmark; Y.
Kilinc, Cukurova University, Medical Faculty, Balcali, Adana, Turkey; K-H.
Kim, Samsung Medical Centre, Seoul, South Korea; S. Kinsey, St James'
University Hospital, Leeds, UK; L. Kjeldsen, Rigshospitalet, Copenhagen,
Denmark; A. Koren, Ha'emek Medical Centre, Afula, Israel; M. E. Lai,
Ospedale Regionale Microcitemie, Cagliari, Italy; Y. Lai, No.1 hospital of
Nanjing Medical University, Nanjing, China; K-H. Lee, Asan Medical Centre,
Seoul, South Korea; S-H. Lee, Royal Adelaide Hospital, Adelaide, Australia; L.
Legros, Hôpital de l'Archet, CHU de Nice, Nice, France; C. Li, Guang Zhou
Nang Fang Hospital, Guangzhou, China; Q. Li, Shanghai No.1 Hospital,
Shanghai, China; W. Linkesch, Med. Univ. Klinik Graz, Graz, Austria; M.
Lübbert, Universitäts klinikum, Freiburg, Germany; D. Lutz, A.Ö. Krankenhaus
der Elisabethinen, Linz, Austria; A. J. Mohamed Thalha, Hospital Universiti
Kebangsaan, Kuala Lumpur, Malaysia; G. Mufti, King's College Hospital,
London, UK; P. Muus, UMC St. Radboud, Nijmegen, The Netherlands; F.
Nobile, Az. Osp. Bianchi Melacrino Morelli, Reggio Calabria, Italy; N.
Papadopoulos, Aristotle University of Thessaloniki, Thessaloniki, Greece; S.
Perrotta, l Policlinico ll Università di Napoli, Napoli, Italy; M. Petrini, Az. Osp.
Ospedali Riuniti S. Chiara, Pisa, Italy; M. Pfeilstöcker, Hanusch-Kranken haus,
Wien, Austria; A. Piga, Ospedale Regina Margherita, Torino, Italy; J. Poole,
Johannesburg Hospital, Johannesburg, South Africa; E. Pungolino, Az, Osp.
Niguarda Ca’ Granda – Università degli Studi di Milano, Milan, Italy; G.
Quarta, Ospedale A. Perrino, Brindisi, Italy; C. Ravoet, H.H. Jolimont Lobbes
(Jolimont), La Louviere, Belgium; A.F. Remacha, Hospital de la Santa Creu i San
Pau, Barcelona, Spain; L. Roy, Centre Jean Bernard, Poitiers, France; G. Saglio,
Az. Sanitaria Ospedale S. Luigi Gonzaga, Orbassano, Italy; G. Sanz, Hospital
La Fe, Valencia, Spain; M. Schmid, Universität Ulm, Ulm, Germany; M.
Schmugge, Kinderspital Zürich, Zürich, Switzerland; H. Schots, Universitair
Ziekenhuis Gent, Gent, Belgium; G. Secchi, Ospedale Civile, Azienda USL 1,
Sassari, Italy; F. Shah, Whittington Hospital, London, UK; H. Shah, General
Hospital Kuala Lumpur, Kuala Lumpur, Malaysia; Z. Shen, Shang Hai Rui Jin
Hospital, Shanghai, China; B. Slama, Centre Hospitalier General, Avignon,
France; P. Sutcharitchan, Chulalongkorn University, Bangkok, Thailand; H.
Tamary, Schneider Children's Medical Centre, Petach Tikva, Israel; K. Taylor,
Mater Hospital, Brisbane, Australia; H-J. Tesch, Onkolog ische
Gemeinschaftspraxis, Frankfurt, Germany; J. Troncy, Hopital Edouard Herriot,
Lyon, France; D. Vassilieff, Hôpital Cochin, Paris, France; A. Villegas, Hospital
Clinico Universitario San Carlos, Madrid, Spain; L. Wainwright, Chris Hani
Baragwanath Hospital, Johannesburg, South Africa; B. Wassmann, Johann
Wolfgang Goethe Universität Frankfurt, Frankfurt, Germany; M. Wettervald,
CHU Dunkerque, Dunkerque, France; A. Will, Manchester Children's Hospital,
Pendlebury, UK; B. Wörmann, Städt. Klinikum Braunschweig, Braunschweig,
Germany; J. Wright, Royal Hallamshire Hospital, Sheffield, UK; S-P. Yeh, China
Medical University Hospital (Taichung), Taichung, Taiwan; S-S. Yoon, Seoul
National University Hospital, Seoul, South Korea; N. C. Zoumbos, Patras
University Medical School, Patras IRO, Greece; S. Zweegman, VUMC,
Amsterdam, The Netherlands.
One-year results from the deferasirox EPIC study
haematologica | 2010; 95(4) 565
©F
err
at
 S
tor
ti F
ou
nd
ati
on
References
1. Olivieri NF. The β-thalassemias. N Engl J
Med. 1999;341(2):99-109.
2. Porter JB. Practical management of iron
overload. Br J Haematol. 2001;115(2):239-
52.
3. Borgna-Pignatti C, Rugolotto S, De Stefano
P, Zhao H, Cappellini MD, Del Vecchio
GC, et al. Survival and complications in
patients with thalassemia major treated
with transfusion and deferoxamine.
Haemato logica. 2004;89(10):1187-93.
4. Leitch HA. Improving clinical outcome in
patients with myelodysplastic syndrome
and iron overload using iron chelation ther-
apy. Leuk Res. 2007;31 (Suppl 3):S7-9.
5. Rose C, Brechignac S, Vassilief D, Beyne-
Rauzy O, Stamatoullas A, Larbaa D, et al.
Positive impact of iron chelation therapy
(CT) on survival in regularly transfused
MDS patients. A prospective analysis by
the GFM. Blood. 2007;110(11):abst 249.
6. Cappellini MD, Cohen A, Piga A, Bejaoui
M, Perrotta S, Agaoglu L, et al. A phase 3
study of deferasirox (ICL670), a once-daily
oral iron che lator, in patients with β-tha-
lassemia. Blood. 2006;107(9):3455-62.
7. Galanello R, Piga A, Forni GL, Bertrand Y,
Foschini ML, Bordone E, et al. Phase II clin-
ical evaluation of deferasirox, a once-daily
oral chelating agent, in pediatric patients
with β-thalassemia major. Haematologica.
2006;91(10):1343-51.
8. Piga A, Galanello R, Forni GL, Cap pellini
MD, Origa R, Zappu A, et al. Randomized
phase II trial of de ferasirox (Exjade®,
ICL670), a once-daily, orally-administered
iron chelator, in comparison to deferoxam-
ine in thalassemia patients with transfu-
sional iron overload. Haematologica. 2006;
91(7):873-80.
9. Porter J, Galanello R, Saglio G, Neufeld EJ,
Vichinsky E, Cappellini MD, et al. Relative
response of patients with myelodysplastic
syndromes and other transfusion-depend-
ent anaemias to deferasirox (ICL670): a 1-yr
prospective study. Eur J Haematol. 2008;
80(2):168-76.
10. Vichinsky E, Onyekwere O, Porter J,
Swerdlow P, Eckman J, Lane P, et al. A ran-
domized comparison of deferasirox versus
deferoxamine for the treatment of transfu-
sional iron overload in sickle cell disease. Br
J Haematol. 2007;136(3):501-8.
11. Jensen PD. Evaluation of iron overload. Br J
Haematol. 2004;124(6):697-711.
12. Valent P, Krieger O, Stauder R, Wimazal F,
Nösslinger T, Sperr WR, et al. Iron overload
in myelodysplastic syndromes (MDS) -
diagnosis, management, and response crite-
ria: a proposal of the Austrian MDS plat-
form. Eur J Clin Invest. 2008;38(3):143-9.
13. Piga A, Fischer R, St Pierre T, Longo F, Fung
E, Engelhardt R, et al. Comparison of LIC
obtained from biopsy, BLS and R2-MRI in
iron overloaded patients with beta-tha-
lassemia, treated with deferasirox
(Exjade®, ICL670). Blood. 2005;106(11):
abst 2689.
14. Olivieri NF, Brittenham GM, Matsui D,
Berkovitch M, Blendis LM, Cameron RG, et
al. Iron-chelation therapy with oral
deferiprone in patients with thalassemia
major. N Engl J Med. 1995;332(14):918-22.
15. Cohen AR, Glimm E, Porter JB. Effect of
transfusional iron intake on response to
chelation therapy in β-thalassemia major.
Blood. 2008;111(2):583-7.
16. Cappellini MD, Galanello R, Piga A, Cohen
A, Kattamis A, Aydinok Y, et al. Efficacy
and safety of deferasirox (Exjade®) with up
to 4.5 years of treatment in patients with
thalassemia major: a pooled analysis.
Blood. 2008;112(11):abst 5411.
17. Taher A, El-Beshlawy A, Elalfy M, Al-Zir K,
Daar S, Habr D, et al. Deferasirox signifi-
cantly reduces iron burden in heavily iron-
overloaded patients with β-thalassaemia:
2.7 year results from the ESCALATOR
study. Haemato lo gica. 2009;94(Suppl 2):82
abst 209.
18. Jensen PD, Heickendorff L, Pedersen B,
Bendix-Hansen K, Jensen FT, Christensen
T, et al. The effect of iron chelation on
haemopoiesis in MDS patients with trans-
fusional iron overload. Br J Haematol. 1996;
94(2):288-99.
19. Kersten MJ, Lange R, Smeets ME,
Vreugdenhil G, Roozendaal KJ, Lameijer W,
et al. Long-term treatment of transfusional
iron overload with the oral iron chelator
defe riprone (L1): a Dutch multicenter trial.
Ann Hematol. 1996;73(5):247-52.
20. al Refaie FN, Hershko C, Hoffbrand AV,
Kosaryan M, Olivieri NF, Tondury P, et al.
Results of long-term deferiprone (L1) thera-
py: a report by the International Study
Group on Oral Iron Chelators. Br J
Haematol. 1995;91(1):224-9.
21. Piperno A. Classification and diagnosis of
iron overload. Haematolo gica. 1998;83(5):
447-55.
22. Porter JB, Huehns ER. Transfusion and
exchange transfusion in sickle cell
anaemias, with particular reference to iron
metabolism. Acta Haematol. 1987;78(2-
3):198-205.
23. Sickle Cell Society. Standards for the clinical
care of adults with sickle cell disease in the
UK. 2008. Available at: http://www.sickle-
cellsociety.org/CareBook.pdf.
24. Brittenham GM, Cohen AR, McLaren CE,
Martin MB, Griffith PM, Nienhuis AW, et
al. Hepatic iron stores and plasma ferritin
concentration in patients with sickle cell
anemia and thalassemia major. Am J
Hematol. 1993;42(1):81-5.
25. Exjade (deferasirox) Prescribing Infor mation.
Novartis Pharma ceuticals Corporation. 2009.
Available at: http://www.pharma.us.novar
tis.com/product/pi/pdf/exjade.pdf.
26. Taher A, Cappellini MD, Vichinsky E,
Galanello R, Piga A, Lawniczek T, et al.
Efficacy and safety of de fe rasirox doses of
>30 mg/kg per d in patients with transfu-
sion-dependent anaemia and iron overload.
Br J Haematol. 2009;147(5):752-9.
27. List AF, Baer MR, Steensma D, Raza A,
Esposito J, Virkus J, et al. Iron chelation
with deferasirox (Exjade®) improves iron
burden in patients with myelodysplastic
syndromes (MDS). Blood. 2008; 112(11):
abst 634.
M.D. Cappellini et al.
haematologica | 2010; 95(4)566
©F
err
at
 S
t r
ti F
ou
nd
ati
on
